Actos
Takeda pays $2.7 billion to settle Actos lawsuits
May 1, 2015Sales and Marketing Actos, FDA, Takeda, bladder, lilly, pioglitazone, type 2
Takeda has agreed to pay $2.7 billion to finally settle thousands of US lawsuits claiming its diabetes drug Actos can …
Takeda offers $2.2 billion to resolve Actos damages claims
April 1, 2015Sales and Marketing Actos, Cancer, Takeda, bladder, diabetes, heart, pioglitazone
Takeda has attempted to settle its hefty damages bill over claims it was hiding cancer risks in its diabetes drug …
New chief executive for Takeda
March 4, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actos, Millennium, Nycomed, Takeda, Yasuchika Hasegawa, christophe weber
Japanese pharma giant Takeda has added the title of chief executive to its representative director, president and chief operating officer …
Analysis finds no Actos bladder cancer link
December 8, 2014Sales and Marketing Actos, Cancer, Takeda, bladder, lilly, pioglitazone, type 2
A large-scale analysis of patient data has found that pioglitazone, the diabetes drug that is the subject of ongoing safety …
Takeda and Lilly get Actos trial reprieve
October 29, 2014Sales and Marketing Actos, Takeda, bladder cancer, diabetes, lilly
A judge has dramatically reduced the $9 billion damages bill Takeda and Lilly were set to pay over safety allegations …
Takeda and Lilly hit with $9 billion Actos damages bill
April 8, 2014Medical Communications, Sales and Marketing Actos, Takeda, law case, lilly
A US jury has ordered Japanese firm Takeda Pharmaceutical to pay $6 billion (£3.6 billion) in punitive damages, over claims …
Generic Actos gains FDA approval
August 20, 2012Sales and Marketing Actos, Mylan, Ranbaxy, Takeda, diabetes, generic
Takeda’s big-selling diabetes pill Actos will have its US sales decimated after the FDA approves three copycat versions of the …
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
European reprieve for Takeda’s Actos
July 22, 2011Sales and Marketing Actos, diabetes
Takeda’s Actos is likely to remain on the market in Europe but regulators want the diabetes drug to carry stronger …
Takeda forced to withdraw Actos in France
July 11, 2011Sales and Marketing Actos, Competact, Takeda, diabetes
Takeda has officially taken its diabetes drug Actos off the market in France at the request of the country’s medicines …
France pulls Takeda diabetes drugs after cancer fears
June 13, 2011Sales and Marketing Actos, Competact, EMA, Takeda
The French medicines agency has moved to prevent two Takeda diabetes drugs from being prescribed after fears they could increase …
FDA launches safety review of Actos
September 20, 2010Sales and Marketing Actos, Takeda, diabetes
A new safety review of Takeda’s diabetes drug Actos has been launched by the FDA after a long-term study suggested …
